Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Nihon Chouzai Co ( (JP:3341) ) has provided an update.
Nihon Chouzai Co., Ltd. reported its consolidated financial results for the nine months ending December 31, 2024, showing a 6.2% increase in net sales compared to the previous year. However, the company’s profit metrics, including EBITDA, operating profit, ordinary profit, and profit attributable to owners of the parent, all experienced significant declines. This financial downturn indicates challenges for Nihon Chouzai in maintaining profitability amidst growing sales, which could impact its market position and stakeholder confidence. Despite these challenges, the company remains committed to its dividend forecast for the fiscal year.
More about Nihon Chouzai Co
Nihon Chouzai Co., Ltd. operates within the pharmaceutical industry, primarily focusing on the management of pharmacies and the provision of related healthcare services and products. The company is listed on the Tokyo Stock Exchange Prime Market and is guided by its President & CEO, Naoto Kasai.
YTD Price Performance: 0.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $253.4M
See more insights into 3341 stock on TipRanks’ Stock Analysis page.
